RxDoctor Payments Data

William Crevier, MD

Internal Medicine · Orland Park, ILNPI 1477509347

Payments from drug & device makers

$10,025in general payments, 2019–2025

Across 531 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$1K
  • Pfizer$816
  • Lilly USA, LLC$773
  • Johnson & Johnson$753
  • Boehringer Ingelheim$623
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$10,013100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,025 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$283,898
Medicare patients
281
Services billed
3,883

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$50,053
FarxigaDapagliflozin Propanediol32$43,568
EliquisApixaban32$42,895
Breztri AerosphereBudesonide/Glycopyr/Formoterol24$21,222
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,856
Tresiba Flextouch U-100Insulin Degludec14$5,987
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen172$5,316
SymbicortBudesonide/Formoterol Fumarate14$5,183
Gabapentin72$2,933
Levothyroxine Sodium180$2,747
Levetiracetam11$2,367
SynthroidLevothyroxine Sodium23$2,084
Metoprolol Succinate124$1,945
Amlodipine Besylate267$1,862
Potassium Chloride84$1,852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,233$69,97470 claims
Novo NordiskOzempic$440$50,05343 claims
PfizerEliquis$816$42,89532 claims
GSKTrelegy Ellipta$1,068$15,85612 claims
AbbVieSynthroid$185$2,08423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Orland Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →